Novel IL-7 Receptor Antagonist Shows Promise in Ulcerative Colitis
(MedPage Today) — SAN DIEGO — Patients with moderate to severe ulcerative colitis experienced clinical, endoscopic, histological, and biological improvements with the first-in-class interleukin (IL)-7 receptor antagonist lusvertikimab compared…
